{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:56Z","timestamp":1787003756877,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16378"],"award-info":[{"award-number":["19K16378"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16314"],"award-info":[{"award-number":["20K16314"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08741"],"award-info":[{"award-number":["20K08741"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H06112"],"award-info":[{"award-number":["17H06112"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H06112"],"award-info":[{"award-number":["17H06112"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H05502"],"award-info":[{"award-number":["18H05502"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pomalidomide and lenalidomide are immunomodulatory agents that were derived from thalidomide. Cereblon (CRBN) is a common direct target of thalidomide and related compounds and works as a Cullin Ring 4 E3 ubiquitin ligase (CRL4) with DDB1, CUL4, and ROC1. The substrate specificity of CRL4\n                    <jats:sup>CRBN<\/jats:sup>\n                    is modulated by thalidomide-related compounds. While lenalidomide is approved for the treatment of several diseases including multiple myeloma, 5q- syndrome, mantle cell lymphoma, and follicular lymphoma, pomalidomide is approved only for the treatment of lenalidomide-resistant multiple myeloma. Here we show that PLZF\/ZBTB16 and its fusion proteins are pomalidomide-dependent neosubstrates of CRL4\n                    <jats:sup>CRBN<\/jats:sup>\n                    .\n                    <jats:italic>PLZF<\/jats:italic>\n                    joins to\n                    <jats:italic>RAR\u03b1<\/jats:italic>\n                    or potentially other partner genes, and the translocation causes leukemias, such as acute promyelocytic leukemia and T-cell acute lymphoblastic leukemia. We demonstrate that pomalidomide treatment induces PLZF-RAR\u03b1 degradation, resulting in antiproliferation of leukemic cells expressing PLZF-RAR\u03b1. This study highlights a potential therapeutic role of pomalidomide as a degrader of leukemogenic fusion proteins.\n                  <\/jats:p>","DOI":"10.1038\/s42003-021-02801-y","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T06:06:09Z","timestamp":1636610769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates"],"prefix":"10.1038","volume":"4","author":[{"given":"Nobuyuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-6795","authenticated-orcid":false,"given":"Tomoko","family":"Asatsuma-Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-9521","authenticated-orcid":false,"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-2664","authenticated-orcid":false,"given":"Takumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2801_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett, J. B., Dredge, K. & Dalgleish, A. G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314\u2013322 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"2801_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333\u2013338 (1998).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2801_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2183\/pjab.96.016","volume":"96","author":"T Ito","year":"2020","unstructured":"Ito, T. & Handa, H. Molecular mechanisms of thalidomide and its derivatives. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 96, 189\u2013203 (2020).","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"2801_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565\u20131571 (1999).","journal-title":"N. Engl. J. Med."},{"key":"2801_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"2801_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nature14628","volume":"523","author":"T Ito","year":"2015","unstructured":"Ito, T. & Handa, H. Myeloid disease: another action of a thalidomide derivative. Nature 523, 167\u2013168 (2015).","journal-title":"Nature"},{"key":"2801_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"2801_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"2801_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"2801_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"2801_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto, J. et al. ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells. Nat. Chem. Biol. 16, 1208\u20131217 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"2801_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41589-019-0366-7","volume":"15","author":"T Asatsuma-Okumura","year":"2019","unstructured":"Asatsuma-Okumura, T. et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. 15, 1077\u20131084 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"2801_CR13","doi-asserted-by":"publisher","first-page":"38430","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7, 38430 (2018).","journal-title":"Elife"},{"key":"2801_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"2801_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59542-x","volume":"10","author":"DG Belair","year":"2020","unstructured":"Belair, D. G. et al. Thalidomide inhibits human iPSC mesendoderm differentiation by modulating CRBN-dependent degradation of SALL4. Sci. Rep. 10, 2864 (2020).","journal-title":"Sci. Rep."},{"key":"2801_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"2801_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"2801_CR18","doi-asserted-by":"publisher","first-page":"0572","DOI":"10.1126\/science.aat0572","volume":"362","author":"QL Sievers","year":"2018","unstructured":"Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, 0572 (2018).","journal-title":"Science"},{"key":"2801_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela, M. E. et al. Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex. Nat. Struct. Mol. Biol. 27, 319\u2013322 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2801_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/nature05731","volume":"446","author":"X Tan","year":"2007","unstructured":"Tan, X. et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640\u2013645 (2007).","journal-title":"Nature"},{"key":"2801_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456\u20131465 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2801_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann, T. M. et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145, 344\u2013349 (2009).","journal-title":"Br. J. Haematol."},{"key":"2801_CR23","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay, A. G. et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114, 4713\u20134720 (2009).","journal-title":"Blood"},{"key":"2801_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","volume":"172","author":"E Rychak","year":"2016","unstructured":"Rychak, E. et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br. J. Haematol. 172, 889\u2013901 (2016).","journal-title":"Br. J. Haematol."},{"key":"2801_CR25","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","volume":"93","author":"A Melnick","year":"1999","unstructured":"Melnick, A. & Licht, J. D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167\u20133215 (1999).","journal-title":"Blood"},{"key":"2801_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1073\/pnas.1717125115","volume":"115","author":"B Chen","year":"2018","unstructured":"Chen, B. et al. Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 115, 373\u2013378 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2801_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An, J. et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat. Commun. 8, 15398 (2017).","journal-title":"Nat. Commun."},{"key":"2801_CR28","doi-asserted-by":"crossref","unstructured":"Davies, F. & Baz, R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. Suppl 1, S13-S19 (2010).","DOI":"10.1016\/S0268-960X(10)70004-7"},{"key":"2801_CR29","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.1073\/pnas.95.21.12123","volume":"95","author":"KF Ahmad","year":"1998","unstructured":"Ahmad, K. F., Engel, C. K. & Prive, G. G. Crystal structure of the BTB domain from PLZF. Proc. Natl Acad. Sci. USA 95, 12123\u201312128 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2801_CR30","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1073\/pnas.92.6.2249","volume":"92","author":"M Cook","year":"1995","unstructured":"Cook, M. et al. Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain. Proc. Natl Acad. Sci. USA 92, 2249\u20132253 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2801_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ng1367","volume":"36","author":"JA Costoya","year":"2004","unstructured":"Costoya, J. A. et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet. 36, 653\u2013659 (2004).","journal-title":"Nat. Genet."},{"key":"2801_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ni.1641","volume":"9","author":"D Kovalovsky","year":"2008","unstructured":"Kovalovsky, D. et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol. 9, 1055\u20131064 (2008).","journal-title":"Nat. Immunol."},{"key":"2801_CR33","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/j.1460-2075.1993.tb05757.x","volume":"12","author":"Z Chen","year":"1993","unstructured":"Chen, Z. et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12, 1161\u20131167 (1993).","journal-title":"EMBO J."},{"key":"2801_CR34","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1182\/blood.V96.12.3894","volume":"96","author":"C Muller","year":"2000","unstructured":"Muller, C. et al. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Blood 96, 3894\u20133899 (2000).","journal-title":"Blood"},{"key":"2801_CR35","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1182\/blood-2009-03-206524","volume":"114","author":"KL Rice","year":"2009","unstructured":"Rice, K. L. et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 114, 5499\u20135511 (2009).","journal-title":"Blood"},{"key":"2801_CR36","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.onc.1201722","volume":"16","author":"M Ruthardt","year":"1998","unstructured":"Ruthardt, M. et al. The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 16, 1945\u20131953 (1998).","journal-title":"Oncogene"},{"key":"2801_CR37","doi-asserted-by":"publisher","first-page":"e15537","DOI":"10.1097\/MD.0000000000015537","volume":"98","author":"X Wang","year":"2019","unstructured":"Wang, X., Wang, J. & Zhang, L. Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review. Medicine 98, e15537 (2019).","journal-title":"Medicine"},{"key":"2801_CR38","doi-asserted-by":"publisher","first-page":"10256","DOI":"10.3171\/2011.1.FOCUS10256","volume":"30","author":"ZA Smith","year":"2011","unstructured":"Smith, Z. A., Buchanan, C. C., Raphael, D. & Khoo, L. T. Ossification of the posterior longitudinal ligament: pathogenesis, management, and current surgical approaches. A review. Neurosurg. Focus 30, 10256 (2011).","journal-title":"Neurosurg. Focus"},{"key":"2801_CR39","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1074\/jbc.M409442200","volume":"280","author":"R Ikeda","year":"2005","unstructured":"Ikeda, R. et al. The promyelotic leukemia zinc finger promotes osteoblastic differentiation of human mesenchymal stem cells as an upstream regulator of CBFA1. J. Biol. Chem. 280, 8523\u20138530 (2005).","journal-title":"J. Biol. Chem."},{"key":"2801_CR40","doi-asserted-by":"publisher","first-page":"40364","DOI":"10.7554\/eLife.40364","volume":"8","author":"S Agrawal Singh","year":"2019","unstructured":"Agrawal Singh, S. et al. PLZF targets developmental enhancers for activation during osteogenic differentiation of human mesenchymal stem cells. Elife 8, 40364 (2019).","journal-title":"Elife"},{"key":"2801_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/ajh\/hpt156","volume":"27","author":"F Liska","year":"2014","unstructured":"Liska, F. et al. Plzf as a candidate gene predisposing the spontaneously hypertensive rat to hypertension, left ventricular hypertrophy, and interstitial fibrosis. Am. J. Hypertens. 27, 99\u2013106 (2014).","journal-title":"Am. J. Hypertens."},{"key":"2801_CR42","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.116.08798","volume":"69","author":"F Liska","year":"2017","unstructured":"Liska, F. et al. Downregulation of Plzf gene ameliorates metabolic and cardiac traits in the spontaneously hypertensive rat. Hypertension 69, 1084\u20131091 (2017).","journal-title":"Hypertension"},{"key":"2801_CR43","doi-asserted-by":"publisher","first-page":"35632","DOI":"10.1371\/journal.pone.0035632","volume":"7","author":"N Wang","year":"2012","unstructured":"Wang, N. et al. Promyelocytic leukemia zinc finger protein activates GATA4 transcription and mediates cardiac hypertrophic signaling from angiotensin II receptor 2. PLoS ONE 7, 35632 (2012).","journal-title":"PLoS ONE"},{"key":"2801_CR44","doi-asserted-by":"publisher","first-page":"105375","DOI":"10.15252\/embj.2020105375","volume":"40","author":"S Yamanaka","year":"2021","unstructured":"Yamanaka, S. et al. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF. EMBO J. 40, 105375 (2021).","journal-title":"EMBO J."},{"key":"2801_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"2801_CR46","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the \u2018undruggable\u2019 cancer targets. Nat. Rev. Cancer 17, 502\u2013508 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2801_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2801_CR48","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","volume":"6","author":"C Fionda","year":"2015","unstructured":"Fionda, C. et al. The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget 6, 23609\u201323630 (2015).","journal-title":"Oncotarget"},{"key":"2801_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature07638","volume":"458","author":"CA Maher","year":"2009","unstructured":"Maher, C. A. et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458, 97\u2013101 (2009).","journal-title":"Nature"},{"key":"2801_CR50","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113\u20131123 (2017).","journal-title":"Blood"},{"key":"2801_CR51","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02801-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T06:11:41Z","timestamp":1675836701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-02801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-02801-y","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"29 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H. has received research support from Bristol Myers Squibb. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1277"}}